The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This pilot study is a Phase IV, single center, placebo-controlled, parallel study design
conducted using the Environmental Exposure Unit (EEU). The study will aim to be determine
whether there are any benefits from Grastek® for the treatment of birch-pollen induced
allergic rhinoconjunctivitis. Grastek® is a Health Canada and FDA approved sublingual
immunotherapy (SLIT) for the treatment of grass-pollen induced allergic rhinoconjunctivitis.
The EEU provides a closed environment in which participants are exposed to a predetermined,
controlled, constant level of airborne pollen. 96 participants will complete this study and
will either receive Grastek® or placebo in a 1:1 ratio. The study will consist of a screening
visit, a pre-treatment pollen exposure visit, 60 days of treatment with Grastek® or placebo,
two treatment visits and a follow-up pollen exposure visit.